학술논문

Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
Document Type
Article
Author
Menzies-Gow, AndrewWechsler, Michael EBrightling, Christopher EKorn, StephanieCorren, JonathanIsrael, ElliotChupp, GeoffreyBednarczyk, ArturPonnarambil, SandhiaCaveney, ScottAlmqvist, GunGołąbek, MonikaSimonsson, LindaLawson, KaitlynBowen, KarinColice, GeneHetzel, Jorge LimaFiterman, JussaraSouza Machado, AdelmirAntila, Martti AntonLima, Marina AndradeMinamoto, Suzana Erico TanniBlanco, Daniela CavaletBezerra, Patricia Gomes de MatosHoule, Pierre-AlainLemiere, CatherineMelenka, Lyle SLeigh, RichardMitchell, PatrickAnees, SyedPek, BonavuthChouinard, GuyCheema, Amarjit SYang, William Ho-ChingPhilteos, GeorgeChanez, PascalBourdin, ArnaudDevouassoux, GillesTaille, CamilleDe Blay, FrédéricLeroyer, ChristopheBeurnier, AntoineGarcia, GillesGirodet, Pierre-OlivierBlanc, François-XavierMagnan, AntoineWanin, StéphanieJust, JocelyneLinde, RichardZielen, StefanFörster, KarinGeßner, ChristianJandl, MargretBuhl, Roland OttoKorn, StephanieKornmann, Marc OliverLinnhoff, AnnelieseLudwig-Sengpiel, AndreaEhlers, MartinSchmoller, TiborSteffen, HeinerHoffmann, MartinKirschner, JoachimSchmidt, OlafWelte, TobiasTemme, HilkeWand, OriBar-Shai, AmirIzbicki, GabrielBerkman, NevilleFink, GershonShitrit, DavidAdir, YochaiKuna, PiotrRewerska, BarbaraPisarczyk-Bogacka, EwaKurbacheva, OksanaMikhailov, Sergey LVasilev, MaksimEmelyanov, AlexanderWali, SirajAlbanna, Amrvan Zyl-Smit, RichardAbdullah, IsmailAbdullah, IsmailBernhardi, DavidHoosen, FarzanaIrusen, ElvisKalla, IsmailLakha, DeepakMitha, EssackNaidoo, VisvakurenNell, HaylenePadayachee, TrevenesanReddy, JeevrenPetrick, Friedrichvan der Walt, EugeneVawda, Zubar Fazal AhmedPark, Hae-SimLee, Sang HaakKim, Mi-KyeongPark, Jung-WonCho, You SookLee, Byung JaeChang, Yoon-SeokPark, Choon-SikLee, Kwan HoLee, Sook YoungYoon, HyoungKyuSohn, Kyoung HeePark, Myung JaeMin, Kyung HoonCho, Young JooPark, Han KiLee, YongChulLee, JaechunSheu, Chau-ChyunTu, Chih-YenLee, Kang-YunBavbek, SevimGemicioglu, BilunEdiger, DaneKalkan, Ilkay KocaMakieieva, NataliiaOstrovskyy, MykolaDytyatkovs'ka, YevgeniyaMostovoy, Yuriy MykhaylovychLebed, KyryloYakovenko, OlehAdams, AtoyaMooring, TimothyTorres Jr, LouisSexton, MarvinThompson, ErnestBernstein, Jonathan ALisi, PaulChappel, Christopher MCole, JeremyGreenwald, Gary IJones, ConigliaroKlein, Ryan MitchellPham, David NSpangenthal, SelwynWeinstein, Steven FWindom, Hugh HKao, Neil LLeong, Mila AMehta, VinayMoore, Wendy CBhat, SaligramaAish, BassilMeltzer, Steven MCorren, JonathanMoss, Mark HKerwin, Edward MDelgado, John PalstedLucksinger, Gregg HudsonThompson, Charles AChupp, GeoffreyAlpizar, Sady AVadgama, Sanjay VirgiZafar, ZahidJacobs, Joshua SLugogo, NJiraJain, NealSher, Lawrence DAndrawis, Nabil SFuentes, DavidBoren, Eric JasonGonzalez, Erika GTalreja, NeetuDurrani, Sheharyar SandyIsrael, ElliotSekhsaria, SudhirDeLeon, SamuelShukla, MayankTotszollosy Tarpay, Martha MFakih, FaisalHudes, GoldaTillinghast, Jeffrey PKorenblat, Phillip EShenoy, KartikQue, LorettaKureishy, Shahrukh AhmadUmeh, Fred ChukwuemekaNguyen, Vinh NhuChu, Hanh ThiNguyen, Thuy Thi Dieu
Source
The Lancet Respiratory Medicine; May 2023, Vol. 11 Issue: 5 p425-438, 14p
Subject
Language
ISSN
22132600; 22132619
Abstract
Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin. The drug has been tested previously in the phase 3 NAVIGATOR (NCT03347279) and SOURCE (NCT03406078) studies, and was subsequently approved as a treatment for severe asthma. This extension study recruited from NAVIGATOR and SOURCE and aimed to evaluate the long-term safety and efficacy of tezepelumab in individuals with severe, uncontrolled asthma.